副主任医师，医学博士 从事软组织肿瘤、腹膜后肿瘤及肝胆胰恶性肿瘤诊疗工作10余年。在上述疾病的手术治疗、围手术期管理、药物治疗及临床试验治疗中积累了丰富的临床经验。在多项针对上述疾病的临床研究中担任PI及Sub-I。主持首都卫生发展科研专项、CSCO临床肿瘤研究基金、北京大学肿瘤医院学科交叉基金、北京大学肿瘤医院院内基金等多项科研项目。获得发明专利1项（第一完成人）。多次获得腹膜后软组织肿瘤、肝胆胰恶性肿瘤辩论赛“最佳辩手”。近几年发表SCI论文10余篇。 以第一作者（共同第一作者）发表下列文章 1. Wang Z, Wu JH, Lv A, Li CP, Tian XY, Hao CY. Anterior Approach to En Bloc Resection in Left-Sided Retroperitoneal Sarcoma with Adjacent Organ Involvement: A Study of 25 Patients in a Single Center. Med Sci Monit. 2018; 24:961-969. 2. Chengxue H, YanHui G, Nina Z, Zhen W, Teli L, Xiaoxia X, Feng W, Hua Z, Zhi Y, Xianteng Y, Lei X. Construction and Application of a PD-L1-Targeted Multimodal Diagnostic and Dual-Functional Theranostics Nanoprobe. Int J Nanomedicine. 2024; 19. 3. Wang Z, Wu J, Lv A, Tian X, Hao C. En bloc resection for intra-abdominal/retroperitoneal desmoid-type fibromatosis with adjacent organ involvement: A case series and literature review. Biosci Trends. 2018; 12:620-626. 4. Wang Z, Wu J, Lv A, Li C, Li Z, Zhao M, Hao C. Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: Novel evidence for extended surgery and a tumor grading system. Biosci Trends. 2018; 12:185-192. 5. Yao Y, Wang Z, Yong L, Yao Q, Tian X, Wang T, Yang Q, Hao C, Zhou T. Longitudinal and time-to-event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma. CPT Pharmacometrics Syst Pharmacol. 2022. 6. Wang Z, Wu JH, Li CP, Lv A, Qiu H, Tian XY, Liu BN, Hao CY. Patients with first recurrent retroperitoneal sarcoma that can be macroscopically completely resected can achieve comparable outcomes with that of primary patients after en bloc resection of tumor and adjacent organs. Front Surg. 2022; 9:956384. 7. Wang Z, Wu J, Tian X, Hao C. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects. Front Med. 2019. 8. Lei X, Yan W, Yanan R, Zhen W, Nina Z, Wenyuan Z, Lixin Z, Ling J, Chengxue H, Xiangxi M, Hua Z, Zhi Y. A whole-body imaging technique for tumor-specific diagnostics and screening of B7-H3-targeted therapies. J Clin Invest. 2025.